Roche's Avastin prolongs colorectal cancer patients' survival

ZURICH (Reuters) - A new study of Roche Holding AG's cancer drug Avastin showed significantly improved survival in patients with metastatic colorectal cancer irrespective of K-Ras gene mutations, the Basel-based drug maker said on Monday.

Continue to Roche's Avastin prolongs colorectal cancer patients' survival on Reuters Health eLine.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz